SLS · SELLAS Life Sciences Group, Inc.

Summary

SELLAS Life Sciences Group, Inc. reported full year 2025 financial results with net loss of $26.9 million, R&D expenses of $16.0 million, and cash and cash equivalents of $71.8 million as of December 31, 2025, plus $42.6 million additional proceeds from warrant exercises in Q1 2026. The company provided updates on Phase 3 REGAL trial progress (72 events as of December 26, 2025) and SLS009 program advancements including first patient dosing and European collaboration.

Key takeaways

• Event Type: Full Year 2025 Financial Results and Corporate Update (Items: 2.02)